Skip to navigation Skip to content

Hereditary transthyretin amyloidosis (HTA) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070419

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised patisiran or vutrisiran for patients with hereditary transthyretin amyloidosis (HTA).

HTA and listing dates

HTA is a hereditary condition characterised by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.

Listing date:

  • patisiran - 1 August 2024
  • vutrisiran - 1 May 2025

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • FAQs from Service Officers
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)

Written Authority Required Drugs